NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company noted that there are currently no approved vaccines or therapies specifically targeting this virus strain.
The company stated that NV-387’s host-targeted antiviral mechanism and oral formulation could offer potential advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. NV-387 is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola.
According to the press release, NV-387 is a broad-spectrum antiviral drug that the company plans to develop for the treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
NanoViricides’ platform technology is based on the TheraCour® nanomedicine technology, which the company licenses from TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license to this technology for several drugs targeting specific human viral diseases, including Ebola/Marburg viruses.
The company’s lead drug candidate NV-387 (API NV-387) is a nanoviricide drug candidate for COVID-19. Another candidate, NV-CoV-2-R, encapsulates remdesivir within its polymeric micelles. The company believes that since remdesivir is already FDA-approved, NV-CoV-2-R could be an approvable drug if safety is comparable.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC.
The full press release is available at https://ibn.fm/aSF5Z.
